Viking Therapeutics, Inc. (VKTX) financials

Viking Therapeutics, Inc. (VKTX) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0, net income of -$360M and diluted EPS of -$3.19.

Revenue (fiscal 2025)

$0

Net income (fiscal 2025)

-$360M

Diluted EPS (fiscal 2025)

-$3.19

Viking Therapeutics, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001607678, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.